1. Home
  2. CTSO vs HBIO Comparison

CTSO vs HBIO Comparison

Compare CTSO & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTSO
  • HBIO
  • Stock Information
  • Founded
  • CTSO 1997
  • HBIO 1901
  • Country
  • CTSO United States
  • HBIO United States
  • Employees
  • CTSO N/A
  • HBIO N/A
  • Industry
  • CTSO Medical/Dental Instruments
  • HBIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • CTSO Health Care
  • HBIO Industrials
  • Exchange
  • CTSO Nasdaq
  • HBIO Nasdaq
  • Market Cap
  • CTSO 68.2M
  • HBIO 13.0M
  • IPO Year
  • CTSO N/A
  • HBIO 2000
  • Fundamental
  • Price
  • CTSO $0.87
  • HBIO $0.30
  • Analyst Decision
  • CTSO Strong Buy
  • HBIO Buy
  • Analyst Count
  • CTSO 3
  • HBIO 2
  • Target Price
  • CTSO $4.67
  • HBIO $4.50
  • AVG Volume (30 Days)
  • CTSO 138.7K
  • HBIO 292.5K
  • Earning Date
  • CTSO 05-14-2025
  • HBIO 05-12-2025
  • Dividend Yield
  • CTSO N/A
  • HBIO N/A
  • EPS Growth
  • CTSO N/A
  • HBIO N/A
  • EPS
  • CTSO N/A
  • HBIO N/A
  • Revenue
  • CTSO $35,594,520.00
  • HBIO $94,135,000.00
  • Revenue This Year
  • CTSO $18.72
  • HBIO N/A
  • Revenue Next Year
  • CTSO $19.75
  • HBIO $8.58
  • P/E Ratio
  • CTSO N/A
  • HBIO N/A
  • Revenue Growth
  • CTSO 14.51
  • HBIO N/A
  • 52 Week Low
  • CTSO $0.70
  • HBIO $0.33
  • 52 Week High
  • CTSO $1.61
  • HBIO $4.08
  • Technical
  • Relative Strength Index (RSI)
  • CTSO 33.89
  • HBIO 25.88
  • Support Level
  • CTSO $0.87
  • HBIO $0.29
  • Resistance Level
  • CTSO $1.16
  • HBIO $0.40
  • Average True Range (ATR)
  • CTSO 0.07
  • HBIO 0.03
  • MACD
  • CTSO -0.02
  • HBIO 0.01
  • Stochastic Oscillator
  • CTSO 0.00
  • HBIO 11.23

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.

Share on Social Networks: